MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE Amex:OPK) today announced that it has acquired exclusive, worldwide rights to a new platform technology for the rapid identification of molecules that can be useful as vaccines and new drugs, and to create new diagnostic tests. The technology was developed at The University of Texas Southwestern Medical Center, by Thomas Kodadek, Ph.D., and his team. Dr. Kodadek, who has recently joined the faculty of The Scripps Research Institute in Jupiter, Florida, will become a consultant to OPKO to oversee the development of this technology and he will also become a member of OPKO’s Scientific Advisory Board.
